Last updated on May 2019

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)


Brief description of study

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

Clinical Study Identifier: NCT03112603

Find a site near you

Start Over

Novartis Investigative Site

Erlangen, Germany
8.68miles
  Connect »